Table 5 Therapeutic genes transferred by rAd in clinical trials

Prostate cancer

Ad5-PSA/MUC1/Brachyury

Prostate-specific antigen (PSA), mucin-1 (MUC1), brachyury

Subcutaneous

Phase I

NCT03481816

[149]

Radiation therapy

Solid tumors

Ad5-CEA/MUC1/Brachyury

Carcinoembryonic antigen (CEA), MUC1, brachyury

Subcutaneous

Phase I

NCT03384316

[150]

Bladder cancer

Ad5-IFNα/Syn3

(Nadofaragene firadenovec)

IFNα2b, syn3

Intravesical

Intravesical Intravesical

Phase III Phase II Phase I

NCT02773849 NCT01687244

[151]

[152]

[153]

Breast cancer

Ad5CMV-p53

p53

Intratumoral

Phase I

NCT00004038

Chemotherapy

Intratumoral

Phase II

NCT00044993

[154]

Chemotherapy

Oral or pharyngeal cancer

Intratumoral

Phase II

NCT00064103

Solid tumor

Intratumoral

Phase II

NCT03544723

Immune checkpoint inhibitors

Lung cancer

DC-rAd.p53

p53, DC vaccine

Intradermal

Phase II

NCT00617409

[155]

Paclitaxel, all -trans retinoic acid

Breast cancer

Intradermal

Phase II

NCT01042535

[156]

Indoximod

Acute myeloid leukemia (AML)

rAd-siSSF

Survivin, MUC1, shRNA

DC vaccine

Inguinal

Phase I

NCT01956630

[145]

Allogenic hematopoietic stem cell transplantation

Head and neck cancer

Ad5-PNP

purine nucleoside phosphorylase (PNP)

Intratumoral

Phase I

NCT01310179

[157]

F-araAMP

Glioma

Ad5-TK, rAd-Flt3L

Thymidine kinase (TK), Fms-like thyrosine kinase 3 ligand (Flt3L)

Intracranial

Phase I

NCT01811992

[158]

Breast cancer

Ad5-TK

Intratumoral

Phase II

[159]

Pembrolizumab

Glioma

Ad5-CD/TKrep

TK, cytosine deaminase (CD)

Perilesional

Phase III

EudraCT, number 2004-000464-28

[160]

Ganciclovir

Prostate cancer

Intraprostatic

Phase I

NCT00583492

[161]

Ganciclovir, 5-FU

Intraprostatic

Phase I

NCT00583492

[162]

Radiation therapy, anciclovir, 5-FU